EPO Experimental Pharmacology and Oncology US Corp.

Based on its 25 years of experience, EPO is offering customized and comprehensive preclinical oncology and immuno-oncology services for the development of novel anti-cancer drugs. Our portfolio includes more than 600 well characterized PDX models of about 17 cancer entities (solid cancers, leukemia), cell line-derived xenograft- as well as syngeneic tumor models. Of note, EPO has long term experience in the establishment of humanized models and has been running studies in these for over a decade.